OneClinical Provides a Full Spectrum of Software Products and Services for the Regulated Life Sciences Industry.
Princeton, NJ-June 12, 2006-Today TAKE Solutions, Inc. announced the formation of the OneClinical™ brand of life sciences offerings as part of its merger with Applied Clinical Intelligence (Philadelphia, PA) and OnSphere Corporation (Raleigh, NC). OneClinical combines a full spectrum of proven data and document management software products and services for clinical trials, drug and device development lifecycles.
"The merger of TAKE Solutions, ACI, and OnSphere enhances our ability to help our clients improve efficiencies in drug and medical device development and product safety. We can now offer our clients global scalability as well as a robust suite of regulatory-compliant process efficiency software" said Dr. Jonathan Seltzer, President, ACI & Chief Medical Officer, TAKE Solutions Global Life Sciences.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.